[{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Pfizer Inc | Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Pfizer Inc | Mundipharma","highestDevelopmentStatusID":"7","companyTruncated":"Charite University, Berlin, Germany \/ Pfizer Inc | Mundipharma"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institut Bergoni\u00e9 \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Institut Bergoni\u00e9 \/ Pfizer Inc"},{"orgOrder":0,"company":"Technische Universit\u00e4t Dresden","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Technische Universit\u00e4t Dresden","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Technische Universit\u00e4t Dresden \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Technische Universit\u00e4t Dresden \/ Pfizer Inc"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MEDSIR \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MEDSIR \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Robert H. Lurie Cancer Center | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California, San Francisco \/ Robert H. Lurie Cancer Center | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Francisco \/ Robert H. Lurie Cancer Center | Pfizer Inc"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"GSK | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Davis \/ GSK | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"University of California, Davis \/ GSK | Pfizer Inc"},{"orgOrder":0,"company":"University of Southern California","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"University of Southern California \/ Pfizer Inc"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Georgetown University \/ Pfizer Inc"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"McMaster University | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Undisclosed","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ McMaster University | Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"St. Joseph's Healthcare Hamilton \/ McMaster University | Pfizer Inc"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Tennessee Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"University of Tennessee Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Tennessee Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Tennessee Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Puma Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Puma Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"AGO Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"AGO Study Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGO Study Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AGO Study Group \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Gabrail Cancer Center Research \/ Pfizer Inc"},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"TACL Consortium \/ Pfizer Inc"},{"orgOrder":0,"company":"Nader Sanai","sponsor":"Barrow Neurological Institute | Ivy Brain Tumor Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Nader Sanai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nader Sanai \/ Barrow Neurological Institute | Ivy Brain Tumor Center","highestDevelopmentStatusID":"6","companyTruncated":"Nader Sanai \/ Barrow Neurological Institute | Ivy Brain Tumor Center"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Georg Hess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Georg Hess","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Georg Hess"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Susana M. Campos, MD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Susana M. Campos, MD","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Susana M. Campos, MD"}]
Find Clinical Drug Pipeline Developments & Deals for Temsirolimus
Details :
The trial examined the local delivery of rapamycin analog (temsirolimus, Torisel) to tissues with the intent to reduce the symptomatic re-obstruction of atherosclerotic arteries below knee after catheter procedures were used to open the vessels and resto...
Details :
Temsirolimus is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peripheral Arterial Disease.
Details :
Temsirolimus is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Peripheral Arterial Disease.
Details :
Temsirolimus is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chronic Limb-Threatening Ischemia.
Details :
Temsirolimus is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Endometrioid.
Details :
Temsirolimus is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder Neoplasms.
Details :
Temsirolimus is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Details :
Temsirolimus is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Details :
Temsirolimus is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Reset All
